These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB; Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K; Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740 [TBL] [Abstract][Full Text] [Related]
9. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Khanna R; Preiss JC; MacDonald JK; Timmer A Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507 [TBL] [Abstract][Full Text] [Related]
11. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P; Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417 [TBL] [Abstract][Full Text] [Related]
12. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M; Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078 [TBL] [Abstract][Full Text] [Related]
13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ; Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164 [TBL] [Abstract][Full Text] [Related]
15. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854 [TBL] [Abstract][Full Text] [Related]